Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.

Some eye doctors were noticing a trend among patients that researchers in Europe now believe has been well demonstrated with data.

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles,

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls significantly when they learn that the weight might come back when the meds are stopped.

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, whether they utilize weight loss drugs or not,” IBX said in a statement.

Indiana’s Medicaid program estimates the Biden administration’s proposal to expand coverage of weight-loss treatment for people with obesity could cost it up to $70 million a year, covering up to 20% of eligible enrollees.